 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Swiss National Bank increased its position in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX  Free Report) by 1.2% during the 2nd quarter, according to the company in its most recent...

Swiss National Bank Grows Stock Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

STAMFORD, Conn., Dec. 05, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced...

SpringWorks Therapeutics Announces Pricing of Upsized Public Offering of Common Stock

ProShare Advisors LLC lifted its stake in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX  Free Report) by 35.6% in the 2nd quarter, according to the company in its most recent 13F...

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Stock Position Raised by ProShare Advisors LLC

STAMFORD, Conn., Dec. 04, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced...

SpringWorks Therapeutics Announces Proposed Public Offering of Common Stock

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX  Free Report)  Equities researchers at Wedbush upped their FY2024 earnings per share (EPS) estimates for shares of SpringWorks Therapeutics...

FY2024 EPS Estimates for SpringWorks Therapeutics, Inc. Raised by Wedbush (NASDAQ:SWTX)

This is a signal that SWTX's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...

SpringWorks Therapeutics (SWTX, $30.42) RSI Indicator left the overbought zone on November 30, 2023

STAMFORD, Conn., Nov. 29, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today...

SpringWorks Therapeutics to Participate in the 6th Annual Evercore ISI HealthCONx Conference

The FDA approved SpringWorks Therapeutics Inc's (NASDAQ: SWTX) Ogsiveo (nirogacestat), an oral gamma-secretase inhibitor, for adult patients with progressing desmoid tumors who read more...

FDA Approves SpringWorks Therapeutics' Lead Therapy As First For Subtype Of Soft Tissue Sarcomas

SpringWorks Therapeutics: Surging On Ogsiveo Approval, Long-Term Outlook Remains Unclear...

SpringWorks Therapeutics: Surging On Ogsiveo Approval, Long-Term Outlook Remains Unclear

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX  Get Free Report) gapped up before the market opened on Tuesday after HC Wainwright raised their price target on the stock from $52.00 to $64.00...

SpringWorks Therapeutics (NASDAQ:SWTX) Shares Gap Up  on Analyst Upgrade

Springworks Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the application of a medicine approach to acquiring, developing, and commercializing medicines. Its pipeline includes Nirogacestat, Mirdametinib, BGB-3245 (RAF Fusion and Dimer Inhibitor), SW-682 (TEAD Inhibitor), and EGFR Inhibitor. The company was founded in August 2017 and is headquartered in Stamford, CT.

Watchers	766
52-Wk Low	$18.00
52-Wk High	$34.16

Market Cap	$2B
Volume (M)	1,459.00
52-Wk High	$34.16
52-Wk Low	$18.00

Current Price	$31.66
Prev Close	$31.90
Open	$31.60
Dividend Yield	0.00%
50-Day Moving Average	$23.23
Beta	1.27
Avg. Volume	1.35M
PE Ratio	-6.48

52-Week High	$34.16
52-Week Low	$18.00
Market Capitalization	$2B
EPS	-$4.88
Price to Book	5.02
Revenue Per Employee	N/A
Enterprise Value/EBITDA	-3.22

SWTX SpringWorks Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals